Premium
Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2‐PK) as a tumor marker for cervical carcinoma
Author(s) -
Kaura Babita,
Bagga Rashmi,
Patel Feruza D.
Publication year - 2004
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/j.1447-0756.2004.00187.x
Subject(s) - pyruvate kinase , medicine , tumor marker , monoclonal antibody , cervical carcinoma , isozyme , glycolysis , tumor m2 pk , enzyme , carcinoma , antibody , pathology , microbiology and biotechnology , cancer research , cervical cancer , cancer , immunology , biology , biochemistry , metabolism
Various isoforms of the glycolytic enzyme pyruvate kinase are expressed in different cell types. One of these isoforms, Tu M2‐PK, is over‐expressed in tumor cells and released into body fluids. Plasma determination of Tu M2‐PK has been shown to discriminate between benign and malignant lesions. Tu M2‐PK was quantitated in the plasma of 50 patients with cervical carcinoma, 10 patients with chronic cervicitis and 10 healthy controls. The concentration of Tu M2‐PK was determined by commercial kits using a sandwich enzyme linked immunosorbent assay based on two monoclonal antibodies (clone I and II) specific for Tu M2‐PK. The sensitivity of the test for discrimination of malignant from non‐malignant condition was 82% with a specificity of 60%. Highly significant statistical difference was found in the means of three groups ( P = 0.0002). The present results indicate that Tu M2‐PK can be used as a tumor marker in follow‐up of patients with cervical carcinoma.